ɔːlðˈoʊ ɚɹˈɪdʒɪnəli aɪdˈɛntᵻfˌaɪd æz ɐn ˌɑːŋkoʊdʒˈɛnɪk fjˈuːʒən ɪn nˈaɪntiːnhˈʌndɹɪd ˈeɪɾi tˈuː, ˈoʊnli ɹˈiːsəntli hɐz ðɛɹ bˌɪn ɐ ɹᵻnˈuːd ˈɪntɹɛst ɪnðə tˌiːˌɑːɹkˈeɪ fˈæmɪli æz ɪt ɹᵻlˈeɪts tʊ ɪts ɹˈoʊl ɪn hjˈuːmən kˈænsɚz bɪkˈʌz ʌvðɪ aɪdˈɛntɪfɪkˈeɪʃən ʌv ˌɛntˌiːˌɑːɹkˈeɪ wˈʌn tˌiːˌɑːɹkˈeɪ ɐ, ˌɛntˌiːˌɑːɹkˈeɪ tˈuː tˌiːˌɑːɹkˈeɪ bˈiː ænd ˌɛntˌiːˌɑːɹkˈeɪ θɹˈiː tˌiːˌɑːɹkˈeɪ sˈiː dʒˈiːn fjˈuːʒənz ænd ˈʌðɚɹ ˌɑːŋkoʊdʒˈɛnɪk ˌɔltɚɹˈeɪʃənz ɪn ɐ nˈʌmbɚɹ ʌv tˈuːmɚ tˈaɪps.
Although originally identified as an oncogenic fusion in 1982, only recently has there been a renewed interest in the Trk family as it relates to its role in human cancers because of the identification of NTRK1 (TrkA), NTRK2 (TrkB) and NTRK3 (TrkC) gene fusions and other oncogenic alterations in a number of tumor types.